| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (NCT01158274) | National Cancer Institute (NCI) | 2010-06-01 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma (NCT01129193) | Amir Mortazavi | 2010-05-04 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (NCT01053494) | Wake Forest University Health Sciences | 2010-04-01 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (NCT01044745) | University of Nebraska | 2009-12-10 |
| FAU in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00769288) | National Cancer Institute (NCI) | 2009-07-01 |
| Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (NCT00601718) | University of Washington | 2007-12-01 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction (NCT00499811) | National Cancer Institute (NCI) | 2007-06-01 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (NCT00489203) | Fred Hutchinson Cancer Center | 2007-04-01 |
| 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00293345) | National Cancer Institute (NCI) | 2006-06-01 |
| PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma (NCT00354185) | National Cancer Institute (NCI) | 2006-05-01 |
| PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (NCT00348985) | National Cancer Institute (NCI) | 2006-03-01 |
| Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (NCT00096005) | National Cancer Institute (NCI) | 2004-11-01 |
| MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas (NCT00098891) | National Cancer Institute (NCI) | 2004-10-01 |
| 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas (NCT00089271) | National Cancer Institute (NCI) | 2004-07-01 |
| Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00077155) | National Cancer Institute (NCI) | 2003-12-01 |
| Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides (NCT00052377) | National Cancer Institute (NCI) | 2002-09-01 |
| Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer (NCT00049504) | Fred Hutchinson Cancer Center | 2002-01-01 |
| Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies (NCT00040846) | Fred Hutchinson Cancer Center | 2001-11-01 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction (NCT00025415) | National Cancer Institute (NCI) | 2001-08-01 |
| 506U78 in Treating Patients With Lymphoma (NCT00005080) | National Cancer Institute (NCI) | 2000-05-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma (NCT00004241) | National Cancer Institute (NCI) | 1999-10-01 |
| Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma (NCT00003970) | National Cancer Institute (NCI) | 1999-01-01 |